Shanghai Stemirna Lands $200 Million to Develop mRNA COVID Vaccine
June 03, 2021 at 07:10 AM EDT
Shanghai 's Stemirna Therapeutics raised nearly $200 million to finance clinical trials and production of its messenger RNA COVID-19 vaccine candidate. The company, located in Zhangjiang Hi-Tech Park, develops immunoncology and infectious disease products using its mRNA technology. It expects its COVID-19 vaccine candidate, which has already started a Phase II trial, will be effective against the South Africa , Brazil and India variants. The financing was led by China Merchants Group's health sector investment arm, Sequoia Capital China and WuXi AppTec. More details.... Share this with colleagues: // //
